Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + cyclophosphamide + bortezomib + dexamethasone
- Development stage
- Phase 3
- Lead developer
- Mayo Clinic
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
Rituximab + cyclophosphamide + bortezomib + dexamethasone (often abbreviated as R-CyBorD or VRCD) is an investigational combination chemoimmunotherapy regimen. It consists of rituximab (an anti-CD20 monoclonal antibody), cyclophosphamide (an alkylating chemotherapy agent), bortezomib (a proteasome inhibitor), and dexamethasone (a corticosteroid). This four-drug regimen has been evaluated in clinical trials, primarily a Phase II study (NCT00711828), for the treatment of patients with relapsed or refractory low-grade B-cell non-Hodgkin lymphomas, including follicular lymphoma, mantle cell lymphoma, and Waldenström macroglobulinemia (lymphoplasmacytic lymphoma).
- Other names
- R-CyBorDR-CyBorD regimenVRCDVRCD regimenrituximab, cyclophosphamide, bortezomib and dexamethasonerituximab, cyclophosphamide, bortezomib, and dexamethasone
02
Targets
CD20 (B-lymphocyte antigen CD20)DNAGR (Glucocorticoid receptor)PSMB5 (Proteasome subunit beta Type-5)PSMB8 (Immunoproteasome)
Beyond the preview
Go deeper on rituximab + cyclophosphamide + bortezomib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + cyclophosphamide + bortezomib + dexamethasone.